Premium
Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
Author(s) -
Sperling Reisa A.,
Aisen Paul S.,
Beckett Laurel A.,
Bennett David A.,
Craft Suzanne,
Fagan Anne M.,
Iwatsubo Takeshi,
Jack Clifford R.,
Kaye Jeffrey,
Montine Thomas J.,
Park Denise C.,
Reiman Eric M.,
Rowe Christopher C.,
Siemers Eric,
Stern Yaakov,
Yaffe Kristine,
Carrillo Maria C.,
Thies Bill,
MorrisonBogorad Marcelle,
Wagster Molly V.,
Phelps Creighton H.
Publication year - 2011
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2011.03.003
Subject(s) - disease , dementia , workgroup , alzheimer's disease , psychology , intervention (counseling) , medicine , prodrome , neuropsychology , cognition , psychiatry , pathology , computer network , psychosis , computer science
The pathophysiological process of Alzheimer's disease (AD) is thought to begin many years before the diagnosis of AD dementia. This long “preclinical” phase of AD would provide a critical opportunity for therapeutic intervention; however, we need to further elucidate the link between the pathological cascade of AD and the emergence of clinical symptoms. The National Institute on Aging and the Alzheimer's Association convened an international workgroup to review the biomarker, epidemiological, and neuropsychological evidence, and to develop recommendations to determine the factors which best predict the risk of progression from “normal” cognition to mild cognitive impairment and AD dementia. We propose a conceptual framework and operational research criteria, based on the prevailing scientific evidence to date, to test and refine these models with longitudinal clinical research studies. These recommendations are solely intended for research purposes and do not have any clinical implications at this time. It is hoped that these recommendations will provide a common rubric to advance the study of preclinical AD, and ultimately, aid the field in moving toward earlier intervention at a stage of AD when some disease‐modifying therapies may be most efficacious.